254.85
254.85 (0%)
As of Apr 28, 2025
ALNYLAM PHARMACEUTICALS, INC. [ALNY]
Source:
Company Overview
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 551-8200 |
| Industry | manufacturing |
| CEO | Alnylam Pharmaceuticals, Inc. |
| Website | www.alnylam.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2,248.2 |
| Operating Profit | $-176.9 |
| Net Income | $-278.2 |
| Net Cash | $153.8 |
Profit Ratios
| Gross Margin | $1,941.7 |
| Operating Margin | -7.9 |
| Profit as % of Revenues | -698.1% |
| Profit as % of Assets | -6.9% |
| Profit as % of Stockholder Equity | -414.6% |
Management Effectiveness
| Return on Equity | -414.6% |
| Return on Assets | -6.6% |
| Turnover Ratio | 55.7% |
| EBITA | $-176.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $4,240 |
| Total Liabilities | $4,172.9 |
| Operating Cash Flow | $-8.3 |
| Investing Cash Flow | $-116.8 |
| Financing Cash Flow | $294.2 |
